Skip to content

Illumina ILMN Total Equity

Total Equity at other companies

Revvity logo
RevvityRVTY
$7.18B-5.9%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$51.93B+5.2%
Azenta logo
AzentaAZTA
$1.55B-8.3%
Pacific Biosciences of California logo
Pacific Biosciences of CaliforniaPACB
$2.37M-97.4%
Personalis, Inc. logo
Personalis, Inc.PSNL
$254.77M+22.9%
Guardant Health logo
Guardant HealthGH
-$181.07M+27.8%

Other financials

Income statement

See full
Revenue$1.1B+4.8%
Gross profit$721.0M+5.6%
Operating income$209.0M+27.4%
Net income$134.0M+2.3%
EPS (diluted)$0.87+6.1%

Balance sheet

See full
Cash & equivalents$1.1B-2.2%
Total debt$2.0B-3.0%
Total assets$6.6B+6.1%

Cash flow

See full
Operating cash flow$289.0M+20.4%
CapEx$38.0M+18.8%
Free cash flow$251.0M+20.7%

Valuation

See full
Market cap$26.6B+91.5%
Enterprise value$27.56B+83.6%
P/E31.2×+20.1×
P/S6.1×+2.8×

Profitability

See full
Gross margin66.2%-0.1pp
Operating margin19.4%
Net margin19.4%+12.7pp
FCF margin22.2%+2.0pp

Returns & leverage

See full
Return on equity33.8%+23.9pp
Debt / equity0.8×-0.1×
Current ratio1.7×-0.1×

Where this comes from

Reported directly by Illumina in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The official record: Illumina’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Illumina's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Illumina's total equity?
Illumina (ILMN) reported total equity of $2.68B in Q1 2026.
How has Illumina's total equity changed year-over-year?
Illumina's total equity increased by 13.0% year-over-year, from $2.37B to $2.68B.
What is the long-term trend for Illumina's total equity?
Over 5 years (2020 to 2025), Illumina's total equity has grown at a -10.3% compound annual growth rate (CAGR), from $4.69B to $2.72B.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.